Israel Englander’s Immix Biopharma IMMX Stock Holding History

Israel Englander’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$21.3M	Buy	2,066,426 +316,226	+18%	+$2.93M	0.01%	1566
2026 Q1	$15.9M	Buy	1,750,200 +90,422	+5%	+$664K	0.01%	1729
2025 Q4	$8.68M	Buy	+1,659,778	New	+$6.83M	﹤0.01%	2413
2024 Q4	–	Sell	-21,521	Closed	-$32.1K	–	6185
2024 Q3	$32.1K	Sell	21,521 -4,779	-18%	-$9.62K	﹤0.01%	5745
2024 Q2	$52.1K	Sell	26,300 -27,981	-52%	-$64.3K	﹤0.01%	5411
2024 Q1	$167K	Buy	+54,281	New	+$210K	﹤0.01%	5439
2022 Q1	–	Sell	-20,470	Closed	-$73K	–	7157
2021 Q4	$73K	Buy	+20,470	New	+$70K	﹤0.01%	6373

Other funds holding IMMX

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Israel Englander's IMMX Position: Q2 2026 in Review

Israel Englander increased its Immix Biopharma (IMMX) stake by 18% in Q2 2026, buying an estimated $2.93M and bringing the position to 2,066,426 shares worth $21.3M. The position accounts for 0.01% of the portfolio, ranked #1566.

Israel Englander first reported a position in IMMX in Q4 2021 and has held it in 7 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Israel Englander held 2,066,426 shares of Immix Biopharma worth $21.3M as of Q2 2026.
Israel Englander bought 316,226 Immix Biopharma shares in Q2 2026, an estimated $2.93M.
Immix Biopharma made up 0.01% of Israel Englander's portfolio in Q2 2026, its #1566 holding.
Israel Englander first reported a position in Immix Biopharma in Q4 2021 and has held it in 7 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.